These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 12504590)
1. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Onda H; Crino PB; Zhang H; Murphey RD; Rastelli L; Gould Rothberg BE; Kwiatkowski DJ Mol Cell Neurosci; 2002 Dec; 21(4):561-74. PubMed ID: 12504590 [TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760 [TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141 [TBL] [Abstract][Full Text] [Related]
4. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405 [TBL] [Abstract][Full Text] [Related]
5. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Inoki K; Li Y; Zhu T; Wu J; Guan KL Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553 [TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809 [TBL] [Abstract][Full Text] [Related]
7. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Corradetti MN; Inoki K; Bardeesy N; DePinho RA; Guan KL Genes Dev; 2004 Jul; 18(13):1533-8. PubMed ID: 15231735 [TBL] [Abstract][Full Text] [Related]
9. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Way SW; McKenna J; Mietzsch U; Reith RM; Wu HC; Gambello MJ Hum Mol Genet; 2009 Apr; 18(7):1252-65. PubMed ID: 19150975 [TBL] [Abstract][Full Text] [Related]
10. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Talos DM; Kwiatkowski DJ; Cordero K; Black PM; Jensen FE Ann Neurol; 2008 Apr; 63(4):454-65. PubMed ID: 18350576 [TBL] [Abstract][Full Text] [Related]
11. Morphology of cerebral lesions in the Eker rat model of tuberous sclerosis. Wenzel HJ; Patel LS; Robbins CA; Emmi A; Yeung RS; Schwartzkroin PA Acta Neuropathol; 2004 Aug; 108(2):97-108. PubMed ID: 15185103 [TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis as an underlying basis for infantile spasm. Yeung RS Int Rev Neurobiol; 2002; 49():315-32. PubMed ID: 12040899 [TBL] [Abstract][Full Text] [Related]
13. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. Feliciano DM; Su T; Lopez J; Platel JC; Bordey A J Clin Invest; 2011 Apr; 121(4):1596-607. PubMed ID: 21403402 [TBL] [Abstract][Full Text] [Related]
14. [Expression of PI3K pathway proteins in refractory epilepsy associated with cortical malformation development]. Ni HC; Sun FH; Piao YS; Ma XL; Lu DH Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):391-5. PubMed ID: 22932407 [TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis: from tubers to mTOR. Kwiatkowski DJ Ann Hum Genet; 2003 Jan; 67(Pt 1):87-96. PubMed ID: 12556239 [TBL] [Abstract][Full Text] [Related]
16. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Ravitz MJ; Chen L; Lynch M; Schmidt EV Cancer Res; 2007 Dec; 67(23):11209-17. PubMed ID: 18056446 [TBL] [Abstract][Full Text] [Related]
17. Biallelic Mutations in Winden KD; Sundberg M; Yang C; Wafa SMA; Dwyer S; Chen PF; Buttermore ED; Sahin M J Neurosci; 2019 Nov; 39(47):9294-9305. PubMed ID: 31591157 [TBL] [Abstract][Full Text] [Related]
18. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960 [TBL] [Abstract][Full Text] [Related]
19. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864 [TBL] [Abstract][Full Text] [Related]
20. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]